Update Regarding Forward Guidance

Renalytix plc

(” Renalytix ” or the ” Company “)

Update Regarding Forward Guidance

LONDON and NEW YORK, 24 September 2025 – Renalytix plc (LSE: RENX) a precision medicine company with kidneyintelX.dkd , the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, provides a further comment regarding revenue guidance following the Company’s announcement dated 23 September 2025.

The Company would like to clarify that the forward revenue guidance provided does not include full consideration of the implications of its recently announced collaboration with Tempus AI , Inc. (“Tempus”). As it is too early to predict revenue contributions from this new relationship with Tempus, the Company expects to provide shareholders with updates in due course.

For further information, please contact:

The person responsible for making this Announcement on behalf of the Company is

James McCullogh, Chief Executive Officer.

About Renalytix ( www.renalytix.com )

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.

Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom’s medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient’s risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.

The over 15,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).

KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about the kidneyintelX,dkd test, visit kidneyintelx.com .